Nathan CA - Imugene Joint Sec
| IMU Stock | 0.04 0 5.41% |
Insider
Nathan CA is Joint Sec of Imugene
| Address | 4-6 Bligh Street, Sydney, NSW, Australia, 2000 |
| Phone | 61 2 9423 0881 |
| Web | https://www.imugene.com |
Imugene Management Efficiency
The company has return on total asset (ROA) of (0.5088) % which means that it has lost $0.5088 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9723) %, meaning that it generated substantial loss on money invested by shareholders. Imugene's management efficiency ratios could be used to measure how well Imugene manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Imugene's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 159 M in 2024, despite the fact that Change To Liabilities is likely to grow to (1.5 M).Similar Executives
| Found 4 records | INSIDER Age | ||
| FCIS FGIA | Perseus Mining | N/A | |
| BSc FAusIMM | Perseus Mining | N/A | |
| Jessica Volich | Perseus Mining | N/A | |
| Christopher Woodall | Perseus Mining | N/A | |
Management Performance
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.51 |
Imugene Leadership Team
Elected by the shareholders, the Imugene's board of directors comprises two types of representatives: Imugene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imugene. The board's role is to monitor Imugene's management team and ensure that shareholders' interests are well served. Imugene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imugene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leslie Chong, MD CEO | ||
| Ursula McCurry, Senior Operations | ||
| MD Woodard, Chief Officer | ||
| John Byon, Senior Development | ||
| BA ASiA, Executive Chairman | ||
| Bradley Glover, Chief Officer | ||
| Bradley MBA, Chief Officer | ||
| Giovanni Selvaggi, Chief Officer | ||
| Nathan CA, Joint Sec | ||
| PharmD MBA, Chief Officer | ||
| ACA BSc, Chief Officer | ||
| Dr BSc, Head Development |
Imugene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imugene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.97 | ||||
| Return On Asset | -0.51 | ||||
| Operating Margin | 22.86 % | ||||
| Current Valuation | 203.56 M | ||||
| Shares Outstanding | 7.57 B | ||||
| Shares Owned By Insiders | 14.38 % | ||||
| Shares Owned By Institutions | 6.60 % | ||||
| Price To Book | 2.50 X | ||||
| Price To Sales | 59.38 X | ||||
| Revenue | 4.97 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Imugene Stock Analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.